VJHemOnc is committed to improving our service to you

BSH 2017 | New trials in relapsed high-grade lymphomas

VJHemOnc is committed to improving our service to you

Graham Collins

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, from the Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses new clinical trials in relapsed high-grade lymphomas at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. He speaks about a planned trial of the PD-1 inhibitor nivolumab as a bridge to stem cell transplantation in relapsed Hodgkin Lymphoma. In high-grade lymphoma, Dr Collins is running the TORCH trial (NCT02752204) of the next-generation mTOR inhibitor vistuserib in relapsed diffuse large B-cell lymphoma. He also highlights the potential of rational combination therapies in relapsed high-grade lymphomas.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter